TMB has been shown to be a biomarker for immune checkpoint inhibitors (ICIs) in melanoma [46], and high TMB acts via anti-CTLA-4 and anti-PD-1 in melanoma and non-small cell lung cancer [41]. Here, CTLA4 is linked to non-small cell lung carcinoma.